Source: CNBC
Summary
Reid Hoffman, a longtime member of Microsoft’s board, is leaving the company to focus on his AI drug discovery startup, Manus. Hoffman co-founded LinkedIn and has been on Microsoft’s board since 2017. He will remain involved with Microsoft as a technology advisor. The departure comes after a decade of significant growth and transformation for Microsoft.
Our Reading
The launch follows a familiar script.
Reid Hoffman trades one high-profile gig for another, this time betting on AI-powered drug discovery. Manus promises to revolutionize the pharmaceutical industry with machine learning. Yet another AI startup claims to disrupt a traditional field. Hoffman’s pivot sounds familiar, and we’ve heard this story before. The real question is, what’s the actual innovation here?
Author: Evan Null
